Novartis

News

Psoriasis and cardio drugs drive Novartis' Q1 sales

Novartis has begun 2019 at a sprint, upgrading its sales forecasts for the year after strong performances from psoriasis drug Cosentyx and cardiology medicine Entresto.

News

Second death in gene therapy trial prompts investigation

A second death in a study of Novartis’ spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) – a potential blockbuster for this rare disease – has prompte

News

Novartis files potential blockbuster eye drug with FDA

Novartis has filed its ophthalmology drug brolucizumab with the US regulator, a potentially strong competitor in the tough market for drugs for the degenerative eye condition wet AMD.

Views & Analysis

R&D Roundup: Pharma gets in on the biotech boom

Some good news for the UK industry in turbulent times is always welcome, and several announcement this month showed us why the biotech sector in the country is looking extremely promising g

News

Novartis completes spin-out of Alcon eye unit

Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products.

News

US drug cost body calls for SMA drug price cuts

A US drug cost-effectiveness group has said that Biogen should cut the price of its already-approved spinal muscular atrophy (SMA) drug, while the $4-$5 million Novartis is suggesting for a

Psoriasis and cardio drugs drive Novartis' Q1 sales

Second death in gene therapy trial prompts investigation

Novartis files potential blockbuster eye drug with FDA

R&D Roundup: Pharma gets in on the biotech boom

Novartis completes spin-out of Alcon eye unit

US drug cost body calls for SMA drug price cuts

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Novartis

Editor's Picks